| Literature DB >> 28666484 |
Maryam Abbasi1, Hojjat Sadeghi-Aliabadi2, Massoud Amanlou3.
Abstract
BACKGROUND: Heat shock protein90 (Hsp90) are overexpressed in tumor cells, so the inhibition of the Hsp90 ATPase activity would be a significantly effective strategy in cancer therapy.Entities:
Keywords: 3,4-Isoxazolediamide; Hsp90; Inhibitor; Molecular docking; Molecular dynamic simulation; QSAR
Mesh:
Substances:
Year: 2017 PMID: 28666484 PMCID: PMC5493083 DOI: 10.1186/s40199-017-0182-0
Source DB: PubMed Journal: Daru ISSN: 1560-8115 Impact factor: 3.117
Fig. 1ATPase cycle in Hsp90. The first, in open state of protein, co-chaperones and client protein bind to C-terminal and middle domain, respectively. ATP bind to N-terminal and Hsp90 is closed. Then ATP is hydrolyzed and the complex changed. Finally, client protein is folded
Fig. 2Several categories of Hsp90 inhibitors. Natural inhibitors (geldanamycin, GM, (1), radicicol (2)), reclaimed analogues of GM (17-AAG (3) and 17-DMAG (4)), synthetic inhibitors (purine (5, PU3), pyrazole (6), indazole (7), aminoquinolines (8, SID: 24724290) and isoxazole (9))
Fig. 3The structure of three clinically Hsp90 inhibitors evaluated in human. Derivative of geldanamycin (17-AAG), carbazol-4-one benzamide (SNX-5422) and isoxazole (NVP-AUY922)
Chemical structures of 3, 4-isoxazolediamides derivatives as Hsp90 inhibitors
*NHCH2CH2 converted to NHCH2CF3
Brief of used descriptors in this study
| Descriptor type | Molecular description |
|---|---|
| Chemical | Surface area, molecular volume, hydration energy, octanol/water partition coefficient (logP), molar refractivity, molar polarisability and molar mass. |
| 0D,1D,2D and 3D | 28 constitutional descriptors, 10 functional groups, 18 atom-centered fragments, 216 topological descriptors, 15 molecular walk counts, 64 BCUT descriptors, 24 Galvestopol. charge indices, 96 2D autocorrelations, 14 charge descriptors, 41 Randic molecular profiles, 27 geometrical descriptors, 150 radial distribution function descriptors (RDF), 160 3D–MoRSE descriptors, 99 WHIM descriptors and 196 GETAWAY descriptors |
| Quantum chemical | Highest occupied molecular orbital energy (EHOMO), lowest unoccupied molecular orbital energy (ELUMO), molecular dipole moment and local charge were obtained with PM3 method in Gaussian 98. Hardness (η = 0.5 (EHOMO + ELUMO)), softness (S = 1/η), electronegativity (χ = 0.5 (EHOMO - ELUMO)) and electrophilicity (ω = χ2/2η) |
The best five models were selected for future analysis
| NO. | Descriptors used | R2 c a | S.Eb | R2 p c | Q2 d | RMSCV e |
|---|---|---|---|---|---|---|
| 1 | X5A, HATS4u, Mor10m, Mor26p, Mor09u, Du | 0.806 | 0.249 | 0.958 | 0.723 | 0.276 |
| 2 | BELe1, MATS6e, Gu, Mor27p, Mor12m, RDF140m | 0.760 | 0.266 | 0.817 | 0.586 | 0.329 |
| 3 | X5A, T (N..O), dipole y, R3e+, R1e, Mor09m | 0.768 | 0.214 | 0.911 | 0.683 | 0.254 |
| 4 | X5A, HATS4u, Mor26p, TIE, dipole z, Mor26e, ISH | 0.814 | 0.245 | 0.883 | 0.723 | 0.274 |
| 5 | X5A, T (N..O), MATS1p, dipole z, MATS8e, Ku, P2m | 0.790 | 0.252 | 0.944 | 0.696 | 0.278 |
aR2 c = Correlation Coefficient of calibration set. bS.E = Standard error of regression. cR2 p = Correlation Coefficient of prediction set. dQ2 = Leave-one-out cross-validation correlation coefficient. eRMSECV = Root mean square error of cross validation
Brief description of the descriptors in five models
| NO. | Name | Description |
|---|---|---|
| 1 | X5A | Connectivity indices-average connectivity index of order 5. |
| 2 | HATS4u | GETAWAY descriptors-leverage-weighted autocorrelation of lag 4 / unweighted. |
| 3 | Mor10m | 3D–MoRSE descriptors-signal 10 / weighted by mass. |
| 4 | Mor26p | 3D–MoRSE descriptors-signal 26 / weighted by polarizability. |
| 5 | Mor09u | 3D–MoRSE descriptors-signal 09 / unweighted. |
| 6 | Du | WHIM descriptors-D total accessibility index / unweighted. |
| 7 | BELe1 | Lowest eigenvalue n. 1 of Burden matrix / weighted by atomic Sanderson electronegativities. |
| 8 | MATS6e | Moran Autocorrelation-lag 6/weighted by atomic Sanderson electronegativities. |
| 9 | Gu | WHIM descriptors-total symmetry index / unweighted. |
| 10 | Mor27p | 3D–MoRSE descriptors-signal 27 / weighted by polarizability. |
| 11 | Mor12m | 3D–MoRSE descriptors-signal 12 / weighted by mass. |
| 12 | RDF140m | Radial Distribution Function-140 / weighted by mass. |
| 13 | T (N..O) | 2D Atom Pairs-sum of topological distances between N..O. |
| 14 | Dipole y | An electric dipole is located along the y axis. |
| 15 | R3e+ | GETAWAY descriptors-R maximal autocorrelation of lag 3 / weighted by Sanderson electronegativity. |
| 16 | R1e | GETAWAY descriptors-R autocorrelation of lag 1 / weighted by atomic Sanderson electronegativities |
| 17 | Mor09m | 3D–MoRSE descriptors-signal 09 / weighted by mass. |
| 18 | TIE | Topological indices-E-state topological parameter. |
| 19 | Dipole z | An electric dipole is located along the z axis. |
| 20 | Mor26e | 3D–MoRSE descriptors-signal 26 / weighted by Sanderson electronegativity. |
| 21 | ISH | GETAWAY descriptors-standardized information content on the leverage equality. |
| 22 | MATS1p | Moran autocorrelation - lag 1 / weighted by atomic polarizabilities |
| 23 | MATS8e | Moran Autocorrelation-lag 8/weighted by atomic Sanderson electronegativities. |
| 24 | Ku | K global shape index / unweighted |
| 25 | P2m | 2nd component shape directional WHIM index / weighted by atomic masses |
Experimental pIC50 and MLR and GA-PLS predicted pIC50
| NO. | Experimental pIC50 | MLR | GA-PLS | NO. | Experimental pIC50 | MLR | GA-PLS |
|---|---|---|---|---|---|---|---|
| 15 | 3.82 | 3.64 | 3.89 | 53 | 4.66 | 4.59 | 3.96 |
| 16 | 3.74 | 3.71 | 4.13 | 54 | 4.62 | 4.65 | 4.57 |
| 17 | 3.79 | 4.13 | 3.52 | 55 | 4.70 | 4.84 | 4.70 |
| 18 | 3.89 | 4.69 | 3.57 | 56 | 4.72 | 4.68 | 4.79 |
| 19 | 4.13 | 3.84 | 3.78 | 57 | 4.08 | 4.48 | 4.41 |
| 20 | 4.43 | 4.25 | 4.29 | 58 | 4.66 | 4.39 | 4.47 |
| 21 | 4.07 | 3.91 | 4.15 | 59 | 3.60 | 4.38 | 3.99 |
| 22 | 3.78 | 4.06 | 4.06 | 61 | 4.40 | 4.41 | 4.30 |
| 24 | 3.80 | 3.67 | 3.74 | 62 | 5.00 | 4.82 | 4.61 |
| 26 | 4.26 | 4.32 | 5.39 | 64 | 3.59 | 4.75 | 3.95 |
| 27 | 4.39 | 4.55 | 4.41 | 65 | 4.32 | 4.72 | 4.15 |
| 28 | 3.72 | 3.70 | 3.81 | 66 | 4.21 | 4.14 | 4.30 |
| 29 | 3.58 | 3.90 | 3.73 | 67 | 4.48 | 4.84 | 4.90 |
| 30 | 3.62 | 3.60 | 3.68 | 68 | 4.47 | 4.62 | 4.61 |
| 31 | 4.62 | 4.44 | 4.33 | 69 | 4.70 | 4.64 | 4.73 |
| 32 | 4.52 | 4.37 | 4.61 | 70 | 4.82 | 5.04 | 4.44 |
| 44 | 4.41 | 4.54 | 4.18 | 73 | 4.40 | 4.26 | 4.39 |
| 45 | 4.85 | 4.60 | 4.42 | 75a | 4.90 | 4.72 | 4.69 |
| 46 | 4.58 | 4.14 | 4.52 | 75d | 4.82 | 4.29 | 4.61 |
| 47 | 4.47 | 4.54 | 4.62 | 79b | 3.67 | 3.72 | 4.55 |
| 48 | 4.47 | 4.72 | 4.34 | 79c | 3.92 | 3.92 | 4.11 |
| 49 | 4.15 | 4.08 | 4.68 | 81a | 3.64 | 3.41 | 3.54 |
| 50 | 4.62 | 4.60 | 4.30 | 81b | 3.37 | 3.49 | 3.74 |
| 51 | 4.49 | 4.52 | 4.53 | 81c | 3.21 | 3.28 | 4.42 |
| 52 | 4.49 | 5.36 | 4.56 | 81d | 2.80 | 3.26 | 4.42 |
Fig. 4a Plot of predicted pIC50 versus the experimental values for MLR model, b GA-PLS model
R2 and Q2 LOO values after ten Y-randomization tests in MLR and GA-PLS
| Iteration | MLR | GA-PLS | ||
|---|---|---|---|---|
| R2 | Q2 LOO | R2 | Q2 LOO | |
| 1 | 0.158 | 0.021 | 0.069 | 0.081 |
| 2 | 0.034 | 0.162 | 0.096 | 0.022 |
| 3 | 0.186 | 0.025 | 0.140 | 0.004 |
| 4 | 0.134 | 0.013 | 0.080 | 0.082 |
| 5 | 0.085 | 0.006 | 0.115 | 0.001 |
| 6 | 0.102 | 0.001 | 0105 | 0.016 |
| 7 | 0.119 | 0.001 | 0.182 | 0.018 |
| 8 | 0.082 | 0.032 | 0.072 | 0.054 |
| 9 | 0.075 | 0.047 | 0.185 | 0.004 |
| 10 | 0.091 | 0.004 | 0.082 | 0.024 |
Fig. 5a William’s plot of generated MLR model, b GA-PLS model
Fig. 6a The position of ligand in X-ray crystallography, b The position of ligand after redocking
Fig. 7a Main cavity in Hsp90, b Four entrance tunnels in back of main cavity
Interactions between the docked 3, 4-isoxazolediamide derivatives and Hsp90 binding site residues
| Comp. | IC50
| ∆ | Hydrogen bonds between atoms of compounds and amino acids | Hydrophobic amino acids | |
|---|---|---|---|---|---|
| Atom of comp. | Amino acid (Distance Å) | ||||
| 15 | 0.153 | −2.08 | Ortho- OH resorcinol ring | Asp93(1.974) | Lys58, Gly135, Ala55, Ile96, Asn106, Met98, Gly97, Asn51, Ser52, Leu107, Phe138, Leu48, Thr184 |
| Para- OH resorcinol ring | HOHa(1.828) | ||||
| 16 | 0.184 | −1.90 | Ortho- OH resorcinol ring | Asp93(1.910) | Lys58, Gly135, Ala55, Ile96, Asn106, Met98, Gly97, Asn51, Ser52, Leu107, Phe138, Leu48,Thr184, Val186 |
| Para- OH resorcinol ring | HOH(1.863) | ||||
| 18 | 0.130 | −2.15 | Para- OH resorcinol ring | Lys58(2.164) | Thr152, Ile96, Ala55, Ser52, Val186, Val150, Leu107, Tyr139, Val136, Ile26, Asp93 |
| HOH(2.153) | |||||
| Ortho- OH resorcinol ring | Asn106(2.155) | ||||
| O atom- isoxazole | HOH (2.632) | ||||
| NH- isoxazole | HOH(2.373) | ||||
| 19 | 0.074 | −2.24 | Para- OH resorcinol ring | Asp93(1.887) | Lys58, Gly135, Ala55, Ile96, Asn106, Met98, Gly97, Asn51, Ser52, Leu107, Phe138, Leu48, Thr184, Val186 |
| HOH(2.085) | |||||
| O atom- isoxazole | HOH(2.153) | ||||
| 20 | 0.037 | −2.85 | Ortho- OH-resorcinol ring | Asp93(1.710) | Leu48, Asn51, Asp54, Ser52, Ala55,Lys58, Ile96, Met98, Leu107, Phe138, Thr184, Val186 |
| Para- OH-resorcinol ring | HOH(1.919) | ||||
| NH- isoxazole | Gly97(2.373) | ||||
| 21 | 0.085 | −2.23 | Para- OH-resorcinol ring | Asp93(2.044) | Leu48, Gly97, Asp54, Ser52, Ala55,Lys58, Ile96, Met98, Asn106, Leu107, Lys112, Gly135, Phe138,T hr184, Val186 |
| Ortho- OH-resorcinol ring | Asn51(1.970) | ||||
| 22 | 0.167 | −1.93 | Ortho- OH-resorcinol ring | Asp93(1.719) | Leu48, Asn51, Asp54, Ser52, Ala55, Lys58, Ile96, Met98, Leu107, Phe138, Thr184, Val186 |
| Para- OH-resorcinol ring | HOH(2.085) | ||||
| NH- isoxazole | Gly97(2.287) | ||||
| 24 | 0.160 | −1.98 | Para- OH resorcinol ring | Asp93(1.819) | Leu48, Gly97, Asp54, Ser52, Ala55, Asn51, Ile96, Met98, Asn106, Leu107, Lys112, Gly135, Phe138, Thr184, Val186 |
| HOH(2.115) | |||||
| O atom- isoxazole | HOH(2.200) | ||||
| F atom-terminal ethyl | HOH(1.813) | ||||
| O atom-methoxy | Lys58(2.105) | ||||
| 26 | 0.055 | −2.58 | Para- OH-resorcinol ring | Asp93(2.225) | Leu48, Asp54, Ser52, Ala55, Asn51, Ile96, Met98, Asn106, Leu107, Phe138, Thr184, Val186 |
| Ortho- OH-resorcinol ring | Gly97(2.064) | ||||
| O atom-terminal ethyl | Lys58(1.812) | ||||
| 27 | 0.041 | −2.59 | Para- OH resorcinol ring | HOH(2.111) | Leu48, Gly97, Asp54, Ser52, Ala55,Lys58, Ile96, Met98, Asn51, Gly95, Asp93, Leu107, Lys112, Gly135, Phe138, Thr184, Val186 |
| O atom-terminal ethyl | HOH(2.459) | ||||
| NH- terminal amid | Asn106(2.124) | ||||
| 28 | 0.190 | −1.92 | Para- OH resorcinol ring | Thr184(1.724) | Asp93, Asp54, Ser52, Ala55, Asn51, Ile96, Met98, Leu107, Phe138, Val186 |
| Ortho- OH-resorcinol ring | Gly97(2.262) | ||||
| NH- isoxazole | HOH(2.022) | ||||
| NH- isoxazole | HOH(1.113) | ||||
| NH- terminal amid | Asn106(2.492) | ||||
| 30 | 0.240 | −1.85 | Para- OH-resorcinol | Ala55(1.640) | Asp93, Asp54, Ser52, Lys58, Asn51, Gly97, Met98, Asn106, Leu107, Phe138, Gly135, Thr184 |
| Ortho- OH-resorcinol | HOH(2.397) | ||||
| 46 | 0.026 | −3.02 | Para- OH-resorcinol ring | Asp93(2.106) | Thr152, Gly97,Ile96, Val186, Ala55, Asp102, Leu107, Tyr132, Gly108, Val136, Ile110 |
| Ortho- OH-resorcinol ring | Asn51(2.058) | ||||
| O atom- isoxazole | Asn51(2.805) | ||||
| NH- isoxazole | HOH(2.433) | ||||
| O atom-methoxy | Lys58(2.933) | ||||
| 57 | 0.084 | −2.31 | Ortho- OH-resorcinol ring | Asp93(1.887) | Leu48, Asn51, Asp54, Ser52, Ala55, Lys58, Ile96, Met98, Leu107, Phe138, Thr184, Val186 |
| Para- OH-resorcinol ring | HOH(1.800) | ||||
| S atom-terminal amid | HOH(1.129) | ||||
| O atom-terminal ethyl | HOH(1.830) | ||||
| NH- isoxazole | Gly97(2.314) | ||||
| 58 | 0.022 | −3.40 | Ortho- OH-resorcinol ring | Asp93(1.799) | Leu48, Asn51, Ser52, Ala55, Lys58, Ile96, Met98, Asn106, Leu107, Phe138, Gly135, Thr184, Val186, Val150 |
| Para- OH-resorcinol ring | HOH(1.773) | ||||
| NH- isoxazole | Gly97(2.375) | ||||
| 59 | 0.250 | −1.84 | Para- OH-resorcinol ring | Thr184(1.814) | Asp93, Leu48,, Asn51, Ser52, Ala55, Lys58, Ile96, Met98, Gly97, Asn106, Leu107, Gly135 |
| O atom-terminal ethyl | HOH(2.385) | ||||
| 61 | 0.040 | −2.68 | Ortho- OH-resorcinol ring | Asp93(1.832) | Leu48, Asn51, Ser52, Ala55, Lys58, Ile96, Met98, Asn106, Leu107, Phe138, Gly135, Thr184, Val186, Val150 |
| Para- OH-resorcinol ring | HOH(1.816) | ||||
| NH- isoxazole | Gly97(2.328) | ||||
| NH-thiazole | HOH(2.308) | ||||
| 64 | 0.260 | −1.82 | Para- OH-resorcinol ring | Lys58(2.045) | Asp93, Asn51, Ser52, Ala55, Asp54, Ile96, Met98, Gly97, Phe138, Gly135, Val136, Tyr139, Asn106, Leu107, Thr184, Val186 |
| HOH(2.032) | |||||
| Ortho- OH-resorcinol ring | Asn106(2.134) | ||||
| O atom- isoxazole | HOH(2.449) | ||||
| NH-isoxazole | HOH(2.340) | ||||
| 65 | 0.048 | −2.62 | O atom- isoxazole | HOH(2.733) | Asp93, Asn51, Ser52, Ala55, Lys58, Ile96, Met98, Gly97, Phe138, Gly135, Val136, Tyr139, Asn106, Leu107, Thr184, Val186 |
| 66 | 0.062 | −2.46 | Para- OH-resorcinol ring | Lys58(2.144) | Asp93, Asn51, Ser52, Asp54, Ala55, Ile96, Met98, Gly97, Phe138, Gly135, Val136, Tyr139, Gly137, Leu107, Thr184, Val186 |
| HOH(1.937) | |||||
| Ortho- OH-resorcinol ring | Asn106(2.074) | ||||
| O atom- isoxazole | HOH(2.477) | ||||
| NH- isoxazole | HOH(2.218) | ||||
| NH-terminal ethyl | Asn106(1.829) | ||||
| 69 | 0.020 | −3.50 | Para- OH-resorcinol ring | HOH(2.022) | Asn51, Ser52, Asp54, Ala55, Lys58, Ile96, Met98, Phe138, Gly135, Val136, Tyr139, Asn106, Leu107, Thr184, Val186 |
| Ortho- OH-resorcinol ring | Asp93(1.909) | ||||
| S atom-terminal amid | HOH(1.969) | ||||
| NH- isoxazole | Gly97(2.365) | ||||
| 73 | 0.040 | −2.80 | Ortho- OH-resorcinol ring | Asp93(2.067) | Asn51, Ser52, Asp54, Ala55, Lys58, Ile96, Gly97, Phe138, Gly135, Val136, Gly137, Leu107, Thr184, Val186 |
| Para- OH-resorcinol ring | HOH(1.968) | ||||
| NH- isoxazole | Met98(2.082) | ||||
| O atom-terminal ethyl | HOH(2.277) | ||||
| 81a | 0.230 | −1.88 | Para- OH-resorcinol ring | Asp93(2.250) | Asn51, Ser52, Asp54, Ala55, Ile96, Met98, Asp106, Thr184 |
| Ortho- OH-resorcinol ring | Gly97(1.942) | ||||
| O atom-terminal ethyl | Lys58(1.888) | ||||
| 81b | 0.430 | −1.76 | Ortho- OH-resorcinol ring | Asp93(1.704) | Lys58, Ser52, Asp54, Ala55, Ile96, Met98, Gly97, Asp106, Leu107, Thr184, Val186 |
| Para- OH-resorcinol ring | HOH(2.099) | ||||
| NH- terminal methoxy | Asn51(2.160) | ||||
| 81c | 0.620 | −1.65 | Ortho- OH-resorcinol ring | Asp93(1.724) | Lys58, Ser52, Asp54, Ala55, Ile96, Met98, Asp106, Leu107, Thr184, Val186, Phe138 |
| Para- OH-resorcinol ring | HOH(1.860) | ||||
| NH- isoxazole | Gly97(2.305) | ||||
| NH-cyclohexane | Asn51(2.153) | ||||
aHOH = Crystallographic water
Fig. 8The predicted novel inhibitors based on QSAR model and docking
Fig. 9Orientation and main interaction between three predicted compounds and Hsp90
Fig. 10The RMSD profile. a Hsp90 backbone in complex with compound 69 (violet), predicted ligand II (green). b Compound 69 (violet), predicted ligand II (green) as a function of simulation time
Fig. 11The gyration radius plot of backbone. Compound 69 (violet), predicted ligand II (green)
Fig. 12The RMSF plot. Hsp90-compound 69 (violet), Hsp90-predicted ligand II (green)
Fig. 133D plots of the interaction between two ligands and Hsp90 at different times during the MD simulation. Column a The interaction of compound 69 with Hsp90. Column b the interaction of the predicted ligand II with Hsp90